Geron is getting out of the business of doing Embryonic Stem cell research. Trust me, if there were any objective truth to the idea that destructive Embryonic Stem cells could make money, the Corp. would stay in.
Earlier this week, the Geron Corporation announced it was abandoning its research into using embryonic stem cells to treat spinal cord injury. Geron was the first company to get the green light from the FDA to conduct clinical trials using embryonic stem cells. That was way back in 2009. And now, citing, quote, “capital scarcity and uncertain economic conditions,” the company is looking to sell off that part of its business and focus on other work.
Pingback: Latest Victory For Regenerative Medicine: Pituitary Grown From Embryonic Stem Cells | Business, the Future and Emerging Tech - December 20, 2011